Nathan Cantoni
Overview
Explore the profile of Nathan Cantoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Condoluci A, Romano I, Dietrich D, Pini K, Stussi G, Muller G, et al.
Blood
. 2025 Feb;
PMID: 40009495
The rationale for combining ibrutinib and venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment lies in their complementary mechanisms of action. Studies investigating IV typically begin with a short initial...
2.
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg J, Spertini O, et al.
Swiss Med Wkly
. 2025 Jan;
155():3885.
PMID: 39877935
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens...
3.
Seydoux C, Satyanarayana Uppugunduri C, Medinger M, Nava T, Halter J, Heim D, et al.
Bone Marrow Transplant
. 2023 Dec;
59(2):294.
PMID: 38129515
No abstract available.
4.
Ben Hassine K, Seydoux C, Khier S, Daali Y, Medinger M, Halter J, et al.
Transplant Cell Ther
. 2023 Dec;
30(3):332.e1-332.e15.
PMID: 38081414
Therapeutic drug monitoring (TDM) of busulfan (Bu) is well-established in pediatric hematopoietic stem cell transplantation (HSCT), but its use in adults is limited due to a lack of clear recommendations...
5.
Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, et al.
Eur J Haematol
. 2023 Oct;
112(3):379-391.
PMID: 37899734
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance and resistance to HU. Methods: This phase...
6.
Schifferli A, Rufer A, Rovo A, Nimmerjahn F, Cantoni N, Holbro A, et al.
Br J Haematol
. 2023 Sep;
203(1):119-130.
PMID: 37735543
Thrombopoietin receptor agonists (TPO-RAs) stimulate platelet production, which might restore immunological tolerance in primary immune thrombocytopenia (ITP). The iROM study investigated romiplostim's immunomodulatory effects. Thirteen patients (median age, 31 years)...
7.
Seydoux C, Satyanarayana Uppugunduri C, Medinger M, Nava T, Halter J, Heim D, et al.
Bone Marrow Transplant
. 2023 Apr;
58(7):811-816.
PMID: 37085674
Busulfan (Bu) combined with cyclophosphamide (Cy) is commonly used as a myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). There is inter-individual variability of Bu pharmacokinetics (PK) and hence...
8.
A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Cantoni N, Sommavilla R, Seitz P, Kulenkampff E, Kahn S, Lambert J, et al.
BMC Cancer
. 2022 Nov;
22(1):1192.
PMID: 36402993
Background: The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European...
9.
Rufer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, et al.
Hemasphere
. 2022 Jun;
6(7):e741.
PMID: 35747588
No abstract available.
10.
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565320
Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland. Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites...